Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 361 to 375 of 551 results for weight management

  1. Frequency of monitoring:- How frequently should children be measured to identify faltering growth?

    faltering growth at an earlier age and contribute to an earlier catch-up in weight. Present practice suggests routine measurements be...

  2. Jejunostomy support after radical surgery:- What is the effectiveness of long-term jejunostomy support compared to intensive dietary counselling and support along with symptom management for people having radical surgery for oesophago-gastric cancer?

    compared to intensive dietary counselling and support along with symptom management for people having radical surgery for...

  3. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

  4. Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

    Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

  5. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.

  6. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

    Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

  7. Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.

  8. Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (TA1039)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.

  9. Injection for more than a million people to help prevent heart attacks and strokes recommended

    People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.

  10. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (HTG379)

    Evidence-based recommendations on Tegaderm CHG securement dressing for vascular access sites in critically ill adults.

  11. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds (MIB208)

    NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .

  12. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  13. High energy liquid feed supplements:- Do high energy liquid feed supplements improve growth in children with faltering growth?

    liquid feed supplements were withdrawn appetite improved with no impact on weight. Further research is important to establish whether...

  14. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.